StopDown
Funding · 22 June 2026Orange Health₹277 CrFull-stack diagnostics platformorangehealth.in ↗

Orange Health Labs raises ₹277 crore Series C

By · Editor ·

Orange Health valuation

Orange Health was valued at ₹1,950 Cr (2026). Orange Health reported revenue of ₹138 Cr in FY26, with a net loss of ₹81 Cr, as reported by Your Story and Entrackr on 22 June 2026.

Orange Health valuation
Valuation (2026)₹1,950 Cr
Revenue (FY26)₹138 Cr
Net loss (FY25)₹81 Cr
Series CBengaluruFounded 2020
  • Orange Health Labs is a full-stack diagnostics platform offering at-home sample collection and own labs
  • It raised ₹277 crore (~$30 million) in Series C funding led by Iron Pillar India
  • The company has served over 3 million orders and achieved 65% YoY revenue growth to ₹138 crore in FY26

What happened

  • Orange Health Labs has raised ₹277 crore (~$30 million) in a Series C funding round.
  • The round was led by Iron Pillar India, which invested ₹156 crore (~$16 million).
  • Other participants include Crescent Enterprises (₹37.7 crore), Bertelsmann (₹21.8 crore), Accel India (₹8 crore), General Catalyst (₹1.8 crore), Good Capital (₹15.5 crore), and Paramark Frontier Fund (₹37 crore).
  • The post-money valuation is approximately ₹1,950 crore ($205 million).
  • Prior to this round, the company had raised about $50 million in total funding.
  • Previous rounds include a $12 million round in 2024 led by Amazon Sambhav Venture Fund and a $25 million Series B in 2022 led by General Catalyst and Bertelsmann India Investments.
  • Accel India remains the largest external shareholder with a 15.49% stake post-Series C, while Iron Pillar India holds 8.0%.

Why it matters

  • India's clinical diagnostics market is expected to reach $4,427.5 million by 2030 at a 10% CAGR (Grand View Research).
  • Orange Health Labs has achieved 65% YoY revenue growth to ₹138 crore in FY26, with an ARR of ₹180 crore.
  • Its Bengaluru operations are at 20% EBITDA profitability, and all other city operations are operationally profitable.
  • The company competes with established players like Dr Lal PathLabs, Redcliffe Labs, and Metropolis India.

The business

  • Orange Health Labs is a full-stack diagnostics platform offering at-home sample collection and its own NABL-accredited and ICMR-certified labs.
  • Customers book tests via the app or website, and an eMedic arrives within 30 minutes for home collection.
  • Reports are delivered within 6 hours for 98% of orders.
  • The company has 750 eMedics, who hold a diploma or degree in medical lab technology and undergo about 100 hours of training.
  • It has served over 3 million orders to date and has over 50,000 Google reviews averaging 4.9/5.
  • Its Net Promoter Score has been above 85 since inception.
  • The platform handles blood, urine, and genetic tests, and has expanded to Delhi, Mumbai, Hyderabad with over 75 walk-in collection centres since 2024.
  • Revenue split: 70% from direct consumers via app/website, 30% from corporate partnerships, insurers, employers, and platforms like Amazon (exclusive partner for pharmacy and diagnostics).
  • It has over 150 corporate partners and over 2,000 clinics onboarded.
  • The company uses in-house software with AI for eMedic assignment, logistics, and report processing, and is ISO 27001 and SOC 2 certified.

The founders

Dhruv Gupta

Founder
in
  • Previously worked in telehealth and diagnostics at Practo.
  • Was inspired to start the company after his wife and daughter contracted dengue in 2019.

Tarun Bhambra

Co-founder
in
  • Former McKinsey consultant and investor.

Who put in money

  • Iron Pillar India lead — Growth-stage venture capital firm investing in Indian tech companies.
  • Crescent Enterprises participated — UAE-based diversified business group with a venture capital arm.
  • Bertelsmann participated — German media, services, and education conglomerate with an investment arm.
  • Accel India participated — Venture capital firm; largest external shareholder with 15.49% stake post-Series C.
  • General Catalyst participated — US-based venture capital firm.
  • Good Capital participated — Early-stage venture capital firm focused on Indian startups.
  • Paramark Frontier Fund participated — Venture capital fund investing in high-growth startups.

In numbers

₹277 CrSeries C amount · 2026
₹1,950 CrPost-money valuation · 2026
$50MTotal funding prior to Series C · 2026
₹138 CrFY26 revenue · 2026
₹180 CrFY26 ARR · 2026
65%FY26 YoY revenue growth · 2026
₹84 CrFY25 revenue · 2025
₹81 CrFY25 loss · 2025
3M+Orders served · 2026
4.9/5Google reviews average · 2026
85+Net Promoter Score · 2026
750eMedics · 2026
150+Corporate partners · 2026
2,000+Clinics onboarded · 2026
75+Walk-in collection centres · 2026
15.49%Accel India stake post-Series C · 2026
8.0%Iron Pillar India stake post-Series C · 2026

What happens next

  • The company plans to expand to new cities, strengthen its omnichannel presence, and widen test categories.

Earlier rounds

  • 2024 · Series · $12M · led by Amazon Sambhav Venture Fund
  • 2022 · Series B · $25M · led by General Catalyst and Bertelsmann India Investments

Up against

Dr Lal PathLabsRedcliffe LabsMetropolis India

Words to know

EBITDA
Earnings Before Interest, Taxes, Depreciation, and Amortisation – a measure of a company's operating profitability.
ARR
Annual Recurring Revenue – the yearly value of subscription-based revenue normalised from a shorter period.
NABL
National Accreditation Board for Testing and Calibration Laboratories – Indian accreditation for testing labs.
ICMR
Indian Council of Medical Research – the apex body for biomedical research in India.

The numbers around it

Orange Health has 2 funding rounds in StopDown's archive.

#The numbers around it
WhenRoundAmountLed by
20 August 2026Round$30 million

Healthcare & Life Sciences in June 2026: 11 rounds with a disclosed amount, $118 million in all; the biggest was Vetic ($40 Mn). Every sector this year →

Other articles talking about it

Read it as a card in the app

Terms in this story

  • Funding stage: Startups raise money in steps called funding stages: pre-seed, seed, Series A, B, C and later, ending in a listing or a sale. Each step is larger and asks for more proof. In India, Series A rounds run from a few million dollars to about $15 million, as of November 2026.
  • Series B/C: Series B, C, D and later rounds are growth rounds: large cheques for a startup with a proven model that wants to expand, enter new markets or move toward profit and a listing. In India they are usually priced in CCPS and, when foreign investors take part, must follow FEMA pricing rules.
  • Financial year: An Indian financial year runs from 1 April to 31 March, and it is named after the year it ends. FY26 means April 2025 to March 2026. Startup results for a year arrive months after it closes, so a November 2026 story may still be about FY25.
  • Lead investor: A lead investor is the investor that sets the price and main terms of a funding round, does the deepest checks on the company and usually puts in the largest cheque. When a headline says a round was led by a fund, that fund was the first to commit and shaped the deal that others joined.

Everything on Orange Health → · All startup news on 22 June 2026 →

Is this Orange Health? Get your “Featured on StopDown” badge →